HPV and oesophageal cancer: insights from ISDE 2021

The 17th World Congress for Esophageal Diseases, organised by the International Society for Diseases of the Esophagus, was held virtually from 27 to 30 September 2021. Scientific sessions, workshops and research abstracts examined high-risk human papillomavirus (HPV), tumour biology and prevention, offering an update for clinicians managing oesophageal squamous cell carcinoma (ESCC). Learn more about 筋萎縮におけるプロテアソーム系とオートファジー.

HPV is a major cause in a distinct subset of oesophageal cancers, alongside tobacco, alcohol and other exposures. For Australian audiences, translating these findings requires attention to diagnostic standards, prevention policy and unequal access to specialist care.

What the congress added to the evidence

Presentations linked high-risk HPV types, particularly 16 and 18, with a variable proportion of ESCC worldwide. Sessions focused on detecting viral activity in tumour tissue and relating it to molecular changes, rather than relying on symptoms or clinical appearance alone.

Congress evidence also needs careful interpretation. Many findings came from abstracts, and reported HPV prevalence varies with population and testing method. The defensible update is that HPV is a significant cause in a subset of ESCC, requiring its own diagnostic and research framework.

How HPV drives malignant change

High-risk HPV can persist in the oesophageal epithelium. Its E6 and E7 proteins disrupt normal cell-cycle controls, while tissue injury and co-carcinogens can accelerate progression. Infection does not invariably produce cancer; persistence, viral integration and host response influence which lesions progress.

Studying persistence also requires attention to host-cell protein turnover. A Japanese review of proteasome and autophagy research offers a useful mechanistic parallel on damaged-cell clearance, although its focus is muscular atrophy rather than HPV.

Australian risk patterns and prevention

Australian interpretation should begin with exposure patterns and health-system differences. Smoking and heavy alcohol remain major drivers, and both are unevenly distributed across communities. Melbourne and Sydney host high-volume referral centres that can compare pathology and outcomes, but national estimates can conceal regional variation.

Aboriginal and Torres Strait Islander communities experience inequitable access to timely specialist care, while some regional and remote patients must travel for endoscopy and specialist pathology. These gaps can influence when symptoms are investigated and which tumour samples are available for HPV testing.

Australia’s school-based HPV vaccination programme, introduced nationally in 2007, strengthens population protection against high-risk HPV. It was designed primarily for cervical prevention, and its relationship to oesophageal cancer remains a research question, not a reason to introduce ESCC screening.

Climate, access and unequal disease burdens

Environmental conditions shape how oesophageal disease presents. A congress article on climate and oesophageal disease provides wider context on changing exposures and disease patterns. In Australia, extreme heat, dehydration and bushfire smoke can complicate hydration and eating or delay care, without establishing HPV as a cause.

Service geography determines whether an early symptom becomes a timely endoscopy. Pathways linking primary care, regional hospitals and metropolitan referral centres can reduce delays. Climate, inequity and access belong in prevention planning, but they do not replace vaccination, tobacco control or alcohol-harm reduction.

Interpreting biomarkers and prognosis

Diagnostic interpretation is where updates can change practice. p16 immunohistochemistry is used as a surrogate in some HPV-related cancers, but it is less specific in oesophageal tissue. HPV DNA or RNA testing, supported by a validated laboratory method, provides complementary evidence that should be interpreted with morphology. Adenocarcinoma arising through Barrett’s oesophagus follows a different pathway.

Prognostic claims also require separation by HPV status, stage, treatment and follow-up. Reporting only a positive antibody stain can obscure whether viral persistence predicts response, recurrence or survival. ISDE 2021 highlighted active research questions here, rather than a settled algorithm for every centre.

Comparing pathways and setting priorities

A clear comparison helps teams decide which measures matter for a specific tumour. HPV-associated and HPV-independent categories are not interchangeable, and neither p16 nor HPV results should be used in isolation. Australian pathology services need a reproducible workflow with consistent specimen handling, transparent reporting and links to treatment evidence.

Different mechanisms carry different prevention priorities. Vaccination, tobacco control and alcohol-harm reduction overlap, while nutritional disorders, caustic injury and inherited conditions require specific attention. HPV-positive and HPV-negative cases should be analysed separately to avoid masking biological differences.

Recommended priorities for Australian services and research networks:

• Agree on HPV and p16 testing criteria with pathology teams, using validated assays and a common reporting template.
• Record smoking, alcohol exposure, prior HPV infection and vaccination history in ESCC datasets.
• Include Aboriginal and Torres Strait Islander community governance and regional representation in national research protocols.
• Establish tissue collections with consistent sample processing and reliable clinical follow-up.
• Analyse HPV-positive and HPV-negative cases separately before drawing conclusions about outcomes.
• Coordinate national datasets through the International Society for Diseases of the Esophagus.

Moving evidence into everyday care

ISDE 2021 connected viral biology, pathology and the realities of clinical care. Australian teams can contribute by measuring variation between HPV-associated and HPV-independent disease, improving access to diagnostic workups and ensuring research includes communities with the greatest burden.

The next concrete step is a 12-month audit of new ESCC cases at each participating centre, recording p16 status, validated HPV testing where available, smoking and alcohol exposure, and barriers to timely endoscopy, with combined findings presented to the International Society for Diseases of the Esophagus.